It is expected that a price bounce should occur soon.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 66 cases where HLSQ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for HLSQ just turned positive on October 05, 2026. Looking at past instances where HLSQ's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
Following a +16.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where HLSQ advanced for three days, in 181 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HLSQ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for HLSQ entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.115) is normal, around the industry mean (2.671). P/E Ratio (-0.009) is within average values for comparable stocks, (16.568). Projected Growth (PEG Ratio) (0.170) is also within normal values, averaging (2.284). Dividend Yield (0.000) settles around the average of (0.125) among similar stocks. P/S Ratio (0.901) is also within normal values, averaging (139.965).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. HLSQ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLSQ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for NIKI just turned positive on October 27, 2026. Looking at past instances where NIKI's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
Following a +2.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where NIKI advanced for three days, in 158 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
NIKI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 50-day moving average for NIKI moved below the 200-day moving average on September 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NIKI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NIKI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.066) is normal, around the industry mean (2.974). P/E Ratio (-0.995) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. NIKI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIKI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
HLSQ | NIKI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 92 | |
PRICE GROWTH RATING 1..100 | 98 | 97 | |
P/E GROWTH RATING 1..100 | 6 | 6 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HLSQ's Valuation (37) in the null industry is in the same range as NIKI (38) in the Pharmaceuticals Major industry. This means that HLSQ’s stock grew similarly to NIKI’s over the last 12 months.
HLSQ's Profit vs Risk Rating (100) in the null industry is in the same range as NIKI (100) in the Pharmaceuticals Major industry. This means that HLSQ’s stock grew similarly to NIKI’s over the last 12 months.
NIKI's SMR Rating (92) in the Pharmaceuticals Major industry is in the same range as HLSQ (100) in the null industry. This means that NIKI’s stock grew similarly to HLSQ’s over the last 12 months.
NIKI's Price Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as HLSQ (98) in the null industry. This means that NIKI’s stock grew similarly to HLSQ’s over the last 12 months.
NIKI's P/E Growth Rating (6) in the Pharmaceuticals Major industry is in the same range as HLSQ (6) in the null industry. This means that NIKI’s stock grew similarly to HLSQ’s over the last 12 months.
| HLSQ | NIKI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 81% |
| Momentum ODDS (%) | N/A | N/A |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | 7 days ago 83% | 23 days ago 81% |
| Declines ODDS (%) | 1 day ago 90% | 6 days ago 90% |
| BollingerBands ODDS (%) | N/A | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HLSQ’s FA Score shows that 1 FA rating(s) are green while NIKI’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HLSQ’s TA Score shows that 4 TA indicator(s) are bullish while NIKI’s TA Score has 5 bullish TA indicator(s).
HLSQ (@Information Technology Services) experienced а -11.22% price change this week, while NIKI (@Biotechnology) price change was -7.88% for the same time period.
The average weekly price growth across all stocks in the @Information Technology Services industry was -0.12%. For the same industry, the average monthly price growth was -2.60%, and the average quarterly price growth was -9.26%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.36%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -14.28%.
HLSQ is expected to report earnings on Nov 11, 2026.
The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.
@Biotechnology (-1.36% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, HLSQ has been loosely correlated with NIKI. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if HLSQ jumps, then NIKI could also see price increases.
| Ticker / NAME | Correlation To HLSQ | 1D Price Change % | ||
|---|---|---|---|---|
| HLSQ | 100% | -2.72% | ||
| NIKI - HLSQ | 60% Loosely correlated | -1.06% | ||
| RDW - HLSQ | 32% Poorly correlated | +6.85% | ||
| FLY - HLSQ | 27% Poorly correlated | +9.01% | ||
| NRIX - HLSQ | 26% Poorly correlated | +4.50% | ||
| AVTX - HLSQ | 26% Poorly correlated | -0.30% | ||
More | ||||
A.I.dvisor indicates that over the last year, NIKI has been loosely correlated with HLSQ. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NIKI jumps, then HLSQ could also see price increases.
| Ticker / NAME | Correlation To NIKI | 1D Price Change % | ||
|---|---|---|---|---|
| NIKI | 100% | -1.06% | ||
| HLSQ - NIKI | 60% Loosely correlated | -2.72% | ||
| CANF - NIKI | 48% Loosely correlated | -4.07% | ||
| APVO - NIKI | 46% Loosely correlated | -14.67% | ||
| ICU - NIKI | 45% Loosely correlated | +2.02% | ||
| MLEC - NIKI | 45% Loosely correlated | -3.29% | ||
More | ||||